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Abstract
Identifying genetic risk factors for parasitic infections such as the leishmaniases could provide important leads for improved 
therapies and vaccines. Until recently most genetic studies of human leishmaniasis were underpowered and/or not replicated. 
Here, we focus on recent genome-wide association studies of visceral leishmaniasis (VL) and cutaneous leishmaniasis (CL). 
For VL, analysis across 2287 cases and 2692 controls from three cohorts identified a single major peak of genome-wide 
significance (Pcombined = 2.76 × 10–17) at HLA-DRB1–HLA-DQA1. HLA-DRB1*1501 and DRB1*1404/DRB1*1301 were the 
most significant protective versus risk alleles, respectively, with specific residues at amino acid positions 11 and 13 unique to 
protective alleles. Epitope-binding studies showed higher frequency of basic AAs in DRB1*1404-/*1301-specific epitopes 
compared to hydrophobic and polar AAs in DRB1*1501-specific epitopes at anchor residues P4 and P6 which interact with 
residues at DRB1 positions 11 and 13. For CL, genome-wide significance was not achieved in combined analysis of 2066 
cases and 2046 controls across 2 cohorts. Rather, multiple top hits at P < 5 × 10–5 were observed, amongst which IFNG-AS1 
was of specific interest as a non-coding anti-sense RNA known to influence responses to pathogens by increasing IFN-γ 
secretion. Association at LAMP3 encoding dendritic cell lysosomal associated membrane protein 3 was also interesting. 
LAMP3 increases markedly upon activation of dendritic cells, localizing to the MHC Class II compartment immediately prior 
to translocation of Class II to the cell surface. Together these GWAS results provide firm confirmation for the importance of 
antigen presentation and the regulation of IFNγ in determining the outcome of Leishmania infections.
Introduction
The leishmaniases are a group of related diseases caused by 
parasites of the genus Leishmania (order Kinetoplastidae, 
family Trypansomatidae). The major clinical presentations 
of leishmaniasis are visceral leishmaniasis (VL) caused by 
members of the L. donovani species complex originating in 
the Old World, and various forms of cutaneous leishmaniasis 
(CL) caused by a wide variety of Old and New World spe-
cies. All species of Leishmania are transmitted by sand flies, 
Phlebotomus spp. in the Old World and Lutzomyia longipal-
pis in the New World. Humans, wild animals and domestic 
animals are known to act as reservoir hosts. VL is charac-
terized by fever, weight loss, epistaxis, pancytopenia, ano-
rexia, abdominal pain, cough, diarrhoea, nausea and vom-
iting, weakness, fatigue, splenomegaly, hepatomegaly and 
lymphadenopathy. As well as being a severe systemic infec-
tion, a proportion of patients treated for VL go on to pre-
sent with cutaneous disease termed post-Kala-Azar dermal 
leishmaniaia (PKDL) (Zijlstra and el-Hassan 2001a; Zijlstra 
et al. 1994). The World Health Organization estimates that 
200,000–400,000 new cases occur annually, 90% of which 
occur in India, Bangladesh, Sudan, South Sudan, Ethiopia 
and Brazil (Alvar et al. 2012). The most common form of CL 
is characterized by localized skin lesions, mainly ulcers, on 
exposed parts of the body. While normally self-limiting, the 
degree of pathology and the rate of healing varies, and the 
lesions leave life-long scars. Mucosal leishmaniasis (ML) 
and disseminated leishmaniasis (DL) are generally preceded 
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by localized CL, the same species of Leishmania causing 
both types of disease. ML leads to partial or total destruc-
tion of mucous membranes of the nose, mouth and throat. 
Over 90% of ML is associated with L. braziliensis infection 
in Bolivia, Brazil, Peru and Paraguay in the New World, and 
with L. aethiopica in Ethiopia in the Old World.
Only a small percentage of individuals infected with 
Leishmania parasites go on to develop clinical disease. 
This variability in rates of clinical disease is determined 
by a complex interplay between parasite, host and vector 
genetic factors, as well as environmental and socioeconomic 
risk factors (Badaro et al. 1986; Chakravarty et al. 2019; 
Hasker et al. 2018; Jeronimo et al. 1994; Peacock et al. 2001; 
Reithinger et al. 2007; Shaw et al. 1995; Zijlstra et al. 1994). 
Immunologically we know a Leishmania-specific cellular 
immune response is a correlate of infection control in resist-
ant individuals, measured traditionally as a positive delayed 
type hypersensitivity skin test responses in vivo (Follador 
et al. 2002; Gomes-Silva et al. 2007; Jeronimo et al. 1994; 
Llanos Cuentas et al. 1984) or lymphocyte proliferation 
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responses ex vivo (Castes et al. 1989; Ho et al. 1982). How-
ever, the different forms of CL are generally associated with 
exaggerated cellular immune responses as measured by these 
parameters, and for both CL and VL we know that a fine 
balance exists between the pro-inflammatory cytokines 
tumour necrosis factor (TNF) and interferon-γ (IFNγ) and 
anti-inflammatory interleukin-10 (IL-10) (Faria et al. 2005a; 
Gautam et al. 2011; Gomes-Silva et al. 2007; Kumar et al. 
2014; Nylen et al. 2007; Nylen and Sacks 2007; Oliveira 
et al. 2014; Singh et al. 2012; Zijlstra and el-Hassan 2001b). 
Thus, it is the balance between antigen-specific pro-inflam-
matory and anti-inflammatory cytokine responses that are 
important in determining the outcome of infection with 
Leishmania parasites. A major interest has been in deter-
mining the extent to which host genetic factors determine 
these responses.
One problem in identifying genetic risk factors for com-
plex parasitic infections [reviewed (Abel et al. 2014; Black-
well 2010; Blackwell et al. 2009; Burgner et al. 2006; Loeb 
2013)] is that most studies undertaken to date have been 
underpowered. This makes it difficult to evaluate chance 
statistical events from real genetic associations. In previous 
reviews (Blackwell 2010; Burgner et al. 2006; Castellucci 
et al. 2014; Mohamed et al. 2019) we provided summary 
tables and/or comprehensive supplementary web tables 
that listed all the studies undertaken in humans up to that 
time looking for susceptibility genes for protozoan parasite 
infections, including leishmaniasis. It is not our intention 
to repeat that exercise here. Rather, we focus on how recent 
genome-wide approaches using well-powered sample sizes 
have uncovered a divergence in the way they highlight spe-
cific genes and pathways involved in susceptibility to the two 
major forms of visceral versus cutaneous disease.
Visceral leishmaniasis
Complex segregation analysis of familial visceral leishma-
niasis (VL) caused by L. chagasi in Brazil favored all genetic 
models over a sporadic model for disease susceptibility, with 
support for all single locus models over polygenic or mul-
tifactorial models of susceptibility (Peacock et al. 2001). 
While a single locus model might seem unlikely given the 
complex nature of a parasitic infectious disease, our recent 
GWAS of VL (Fakiola et al. 2013) (Fig. 1a), conducted as 
part of phase 2 of the Wellcome Trust Case–Control Con-
sortium, highlighted the polymorphic HLA-DR-DQ region 
within the major histocompatibility complex of immune-
related genes as the single major genetic determinant of VL 
(Pcombined = 2.76 × 1017; odds ratio = 1.41; 95% confidence 
interval = 1.30–1.52 over three cohorts). This replication 
across three independent cohorts crossed the geographi-
cal and epidemiological divides of continent and etiologi-
cal parasite species, L. donovani in India and L. infantum/
chagasi in Brazil. This robust demonstration that the most 
important genetic risk factor for VL lies at the heart of elic-
iting host CD4 + T-cell-mediated immunity against Leish-
mania parasites has major implications for vaccine design, 
allowing researchers to pursue single-minded post-GWAS 
functional analyses designed to understand the host–parasite 
interaction at a high resolution molecular level of antigen 
presenting cell function. Indeed, fine mapping (Fig. 1b) 
demonstrated that HLA-DRB1*1501 and DRB1*1404/
DRB1*1301 were the most significant protective versus risk 
alleles, respectively, with specific residues at amino acid 
positions 11 and 13 unique to protective alleles (Singh et al. 
2018). To determine the nature of epitopes binding to risk 
versus protective DRB1 alleles both in silico and in vitro 
experimental approaches were employed. NetMHCIIPan2.1 
(Nielsen et al. 2010) was used to map epitopes and bind-
ing affinities across 49 Leishmania vaccine candidates, 
and across peptide epitopes captured from dendritic cells 
treated with crude Leishmania antigen and identified using 
mass spectrometry and alignment to a reference Leishmania 
genome (Singh et al. 2018). In these studies, greater peptide 
promiscuity was observed in sequence motifs for 9-mer core 
epitopes predicted to bind to risk (*1404/*1301) compared 
to protective (*1501) DRB1 alleles. In addition, there was 
a higher frequency of basic AAs in DRB1*1404-/*1301-
specific epitopes compared to hydrophobic and polar AAs 
in DRB1*1501-specific epitopes (Fig. 1c) at anchor residues 
P4 and P6 which interact with residues at DRB1 position 
11 and 13 (Fig. 1d). Peptides prepared based on sequences 
Fig. 1  Journey from GWAS to function in understanding the role 
of HLA-DRB1 as the single important genetic risk factor in VL. a 
Manhattan plot for meta-analysis across independent cohorts of VL 
caused by L. donovani in India and L. infantum/chagasi in Brazil 
(Fakiola et  al. 2013). b Forest plot showing associations between 
VL and classical DRB1 alleles (Singh et al. 2018). c WebLogo plots 
for sequence motifs that characterize 9-mer cores for epitopes bind-
ing preferentially to the protective DRB1*1501 compared to the 
DRB1*1401 risk allele (Singh et  al. 2018). Polar amino acids are 
green (G, S, T, Y, C) or purple (Q, N), basic amino acids are blue 
(K, R, H), acidic amino acids are red (D, E), and hydrophobic amino 
acids are black (A, V, L, I, P, W, F, M). The size of the letter indi-
cates the frequency with which the amino acid is found in this posi-
tion of core 9-mers, and the overall peak height on the y-axis indi-
cates the degree of conservation for specific epitopes at this location. 
Greater promiscuity and a higher frequency of basic amino acids in 
DRB1*1401-specific epitopes, compared with hydrophobic and polar 
amino acids in DRB1*1501-specific epitopes, at anchor residues 
P4 and P6 which interact with residues at DRB1 positions 11 and 
13. d Model of epitope binding to the DRA/DRB alpha/beta dimer 
demonstrating the specific interaction between amino acids at posi-
tions 4 and 6 in the 9-mer cores of Leishmania antigenic epitopes that 
bind to pockets 4 and 6 created by amino acids at positions 11 and 
13 in the DRB1 molecule. e Shows the higher ratio of IFNG:IL10 
in cytokine responses to peptides based on epitopes captured den-
dritic cells homozygous for the protective DRB1*1501 allele com-
pared to epitopes captured from dendritic cells homozygous for the 
DRB1*1301 risk allele (Singh et al. 2018)
◂
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of epitopes captured from risk versus protective alleles 
were then used in whole blood cytokine assays to deter-
mine whether these differences in epitope-binding affected 
the important balance between pro- and anti-inflammatory 
cytokines. Cured VL patients made variable but robust IFN-
γ, TNF and IL-10 responses to 20-mer peptides based on 
captured epitopes, with peptides based on DRB1*1501-
captured epitopes resulting in a higher proportion (odds 
ratio 2.23; 95%CI 1.17–4.25; P = 0.017) of patients with 
IFN-γ:IL10 ratios > twofold compared to peptides based 
on DRB1*1301-captured epitopes (Fig. 1e). These genetic 
studies have, therefore, led to a greater understanding of 
the molecular interactions between host antigen presenting 
cell molecules and antigenic epitopes of the pathogen that 
drive the immune response towards either a protective or a 
disease-associated response.
GWAS data for the Indian and Brazilian cohorts were 
also examined separately using a less stringent cutoff of 
P < 1 × 10–5 to look for potential population-specific asso-
ciations. None of the regions associated at P < 1 × 10–5 in 
these separate analyses showed significant association in the 
combined analysis. Of the hits that were population-specific 
(one for India; 13 for Brazil), 8 were in intergenic regions 
and the remainder landed in genes with no obvious func-
tional significance (Table S1).
Cutaneous leishmaniasis
Human family-based genetic epidemiology studies of 
CL disease caused by L. peruviana were consistent with 
a gene by environment multifactorial model, with a two-
locus model of inheritance providing the best fit to the 
data (Shaw et al. 1995). This suggested that major genetic 
risk factors might also readily be found for CL disease. A 
GWAS was considered the best way to test this hypothesis. 
Genome-wide genetic analysis was undertaken (Castellucci 
et al. 2020) using DNAs from 2066 cases of CL caused by 
L. braziliensis and 2046 controls across two independent 
cohorts. The rarer forms of ML and DL disease caused by 
L. braziliensis were not used in this study due to lack of 
statistical power. Linear mixed models were employed in 
FastLMM (Lippert et al. 2011) to take account of relat-
edness, multiple testing and population heterogeneity. 
Combined analysis across these cohorts that were simi-
larly powered to the VL study found no associations that 
achieved genome-wide significance, commonly accepted as 
P < 5 × 10–8 for studies employing variants with minor allele 
frequencies > 0.05 (Dudbridge and Gusnanto 2008; Fadista 
et al. 2016; Peer et al. 2008). Rather, multiple top hits at 
P < 5 × 10–5, consistent with complex disease inheritance, 
were observed that included some plausible novel candi-
date susceptibility genes. Amongst these were SERPINB10 
(Pcombined = 2.67 × 10–6), CRLF3 (Pcombined = 5.12 × 10–6), 
S T X 7  ( P c o m b i n e d  =  6 . 0 6  ×  1 0 – 6 ) ,  K R T 8 0 
(Pcombined = 6.58 × 10–6), LAMP3 (Pcombined = 6.54 × 10–6) 
and IFNG-AS1 (Pcombined = 1.32 × 10–5). Effect sizes for 
these associations were small (odds ratios 1.07–1.21) (Cas-
tellucci et al. 2020) and lower than those observed for the top 
single nucleotides HLA variant associated with VL (odds 
ratio 1.49–1.50 Indian discovery; 1.38–1.67 Brazilian dis-
covery) (Fakiola et al. 2013). To obtain functional support 
for these associations, published expression data (Novais 
et al. 2015) available on GEObase (GSE55664) was inter-
rogated. LAMP3, STX7 and CRLF3 were all shown to be 
expressed more highly in CL biopsies compared to normal 
skin, whereas expression of KRT80 was strongly reduced 
(Castellucci et al. 2020). SERPINB10 was not expressed in 
skin, while probes were not available on the chip employed 
(Novais et al. 2015) for IFNG-AS1. Nevertheless, IFNG-
AS1 was of specific interest as a non-coding anti-sense RNA 
known to influence responses to pathogens by increasing 
IFN-γ secretion in T cells and NK cells (Collier et al. 2012; 
Gomez et al. 2013; Petermann et al. 2019). Association at 
LAMP3 encoding dendritic cell lysosomal associated mem-
brane protein 3 was also interesting. LAMP3 increases 
markedly upon activation of dendritic cells, localizing to the 
MHC Class II compartment immediately prior to transloca-
tion of Class II to the cell surface (de Saint-Vis et al. 1998). 
Together these GWAS results strengthen our knowledge of 
the importance of antigen presentation and the regulation of 
IFNγ in determining the outcome of Leishmania infections.
Do GWAS data provide support for previous 
candidate gene studies?
Data from the VL and CL GWAS provide the opportunity to 
evaluate earlier candidate gene studies which, as suggested 
above, were frequently compromised by lack of statistical 
power and/or were not replicated. Prior to the GWAS, fam-
ily-based genome-wide linkage studies together with studies 
in mouse models had highlighted putative non-HLA candi-
date susceptibility genes for VL. These included CXCR2, 
CXCR1, SLC11A1, DLL1, CCL1, CCL16, and IL2RB 
(Bucheton et al. 2007; Fakiola et al. 2011; Jamieson et al. 
2007; Mehrotra et al. 2011; Mohamed et al. 2004). None 
of these loci showed consistent association in the Indian or 
Brazilian cohorts used for the GWAS analysis, even when 
looking at precisely the same single nucleotide variant (Faki-
ola et al. 2013). Four of the original candidate gene studies 
were undertaken in The Sudan, which could indicate some 
geographic or ethnic heterogeneity in genetic risk factors for 
VL and/or differences in the parasite. On balance, however, 
it seems unlikely that variants in these genes remain strong 
candidates as genetic risk factors for VL.
For CL, candidate gene studies (Almeida et  al. 2015; 
Cabrera et al. 1995; Castellucci et al. 2006, 2010, 2011, 2012, 
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2014; Ramasawmy et al. 2010; Salhi et al. 2008) undertaken in 
L. braziliensis endemic regions had demonstrated associations 
with polymorphisms at multiple genes associated with pro- and 
anti-inflammatory responses (TNFA, SLC11A1, CXCR1, IL6, 
IL10, CCL2/MCP1) and/or with wound healing (FLI1, CTGF, 
TGFBR2, SMAD2, SMAD3, SMAD7, COL1A1) in determin-
ing susceptibility to CL or ML disease. This included suscep-
tibility genes identified from murine studies of leishmaniasis 
(SLC11A1, FLI1) (Castellucci et al. 2010, 2011). Although 
frequently underpinned by functional data (Castellucci et al. 
2006; Ramasawmy et al. 2010; Salhi et al. 2008) and/or sup-
ported by prior immunological studies (Bacellar et al. 2002; 
Castes et al. 1993; D’Oliveira et al. 2002; Faria et al. 2005b; 
Lessa et al. 2001), these studies had also generally lacked sta-
tistical power. Given a priori evidence to look at these genes 
in the GWAS data, a value of Pcombined < 0.01 was used as a 
cutoff to identify possible associations. No variants were asso-
ciated at Pcombined < 0.01 for TNFA, SLC11A1, CXCR1, IL6, 
IL10, CCL2/MCP1, FLI1, CTGF, COL1A1, or TGFBR2 in 
the CL GWAS data (Castellucci et al. 2020). This failure to 
replicate may, in some cases, be due to the fact that only the 
CL phenotype was examined in the GWAS, and not ML or DL 
disease. Associations were observed for variants at SMAD2 
(P = 1.47 × 10–4), SMAD3 (P = 0.009) and SMAD7 (P = 0.005), 
wound healing genes that had previously been shown to be 
associated with CL (Castellucci et al. 2012). Some evidence for 
associations at related SMADs was also observed, specifically 
at SMAD1 (P = 7.49 × 10–4), SMAD4 (P = 1.90 × 10–4), SMAD6 
(P = 0.001), and SMAD9 (P = 0.004). The major role for SMAD 
proteins is to transduce signals from receptors of the transform-
ing growth factor beta superfamily. Although no association at 
Pcombined < 0.01 was observed at TGFBR2, association at the 
functionally related gene TGFBR3 (P = 3.98 × 10–4) was sup-
ported at multiple variants across the gene. Similarly, associa-
tions observed at collagen genes, COL24A1 (P = 2.06 × 10–4) 
and COL11A1 (P = 6.22 × 10–4), functionally related to wound 
healing gene COL1A1, were supported at multiple variants 
across each gene. Associations were also observed for variants 
at genes, IL6R (P = 7.14 × 10–4) and IL10R (P = 0.003), encod-
ing receptors for cytokines IL-6 and IL-10 that have previously 
been shown to be genetically or functionally associated with 
CL. On balance, results of the CL GWAS provided more sup-
port for previously identified candidate genetic risk factors than 
had the VL GWAS data.
Conclusions
The results of these GWAS studies provide contrasting sto-
ries in relation to genetic risk factors for VL compared to 
CL disease. Whereas a single association at genome-wide 
significance was observed for VL (Fakiola et al. 2013), the 
results of the CL GWAS showed multiple potential genetic 
risk factors all with small effect sizes and none achieving 
genome-wide significance (Castellucci et al. 2020). The lat-
ter is consistent with polygenic inheritance for a multifacto-
rial complex infectious disease. Much larger studies would 
be required to determine whether any of these putative 
susceptibility loci would ever achieve genome-wide signifi-
cance. To better understand the pathogenesis of VL and CL 
disease, it is likely that a more cost-effective approach will 
be to use the current GWAS data in combination with func-
tional expression studies that can be carried out on fewer 
individuals. This will certainly be true for the rarer forms 
of disease such as ML, DL or PKDL, where obtaining the 
sample size required to achieve genome-wide significance 
in genetic studies would be very difficult. This does not, 
however, preclude the possibility that future large-scale 
sequencing projects may become affordable and reveal yet 
uncovered genetic risk factors, especially in the context of 
these rarer forms of disease.
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